A combination of CBD and terpenes was three time more effective in stopping coronavirus-related inflammation run amok compared to dexamethasone.

Public health officials have lamented the rush to locate a reliable Covid-19 treatment has led to “desperation science,” marked by maverick experimentation and faulty research. And while skeptics may lump cannabis in with that description, early trial results indicate otherwise.

Jesse Bontecou, deputy director of industry group Oregon Retailers of Cannabis Association (ORCA), recalls how the group once tried to promote an event on Facebook.

It was in 2018 or early 2019, he recalls, and included the state’s top cannabis regulator giving a talk on cannabis policy. Facebook not only rejected the post, but also dinged the group with a warning, Bontecou said. ORCA is a trade association—“and yet we’ve had problems with Facebook,” he said. “It’s frustrating.”

He wonders at times if the association’s account will get suspended. “I’m even nervous talking to you about it,” he said.

The gears of automated delivery management were in motion long before the arrival of Uber and other sharing services. Tech behemoths like Amazon had already shattered the glass ceiling on next-day delivery, but their buffet of consumer products was missing many of the smaller markets. 

Both a product of compliance and payment issues, large corporations like Amazon simply didn’t offer the delivery of products like marijuana. Only four years after Proposition 64 in California, the bespoke delivery market for cannabis products remains ripe for disruption, with the lack of a major player leaving a void. 

For many people, coffee is a crucial part of their morning routine (read: I can't function without large quantities of caffeine). While coffee can feel like magical get-stuff-done juice, too much of a good thing can leave you jittery, anxious, and seriously over-caffeinated. 

We’re told all the time to fear synthetic cannabinoids, and to stay away from products that might use them. But are they really that dangerous? And aren’t most approved medical cannabis treatments still made from them?

According to drugabuse.org, “Synthetic cannabinoids are human-made mind-altering chemicals that are either sprayed on dried, shredded plant material so they can be smoked or sold as liquids to be vaporized and inhaled in e-cigarettes and other devices. These products are also known as herbal or liquid incense. These chemicals are called cannabinoids because they are similar to chemicals found in the marijuana plant.”

In early September 2019, President Trump expressed an urgency to ban vaping products.

In the wake of this announcement, the Center for Drug Control (CDC) reported that 1,299 confirmed and probable lung injury cases were associated with e-cigarette or vaping products.

In addition, the CDC confirmed 26 deaths related to vaping products. However, this wasn’t the first instance of bad press for vaping.

A History of the Vaping Crisis

Like many of today’s technologies, vaping and e-cigarettes seemed to skyrocket in popularity overnight. The credit is largely due to Juul.

Canadian researchers are hoping to fill in the gaps regarding how effective medicinal marijuana is in treating adults with chronic pain, sleep, anxiety and depression issues as part of a new six-month study.

After over a century of irresponsible treatment of our environment, our plant -humanity is in need of a quick solution. Hemp may just be one of the pieces to this giant puzzle.

Unfortunately, hemp didn’t have the opportunity to help us until recently due to poor regulation. Back in the 1930s, marijuana was criminalized as a dangerous substance that caused violent behaviors and had a high potential for addiction. When this happened, hemp was criminalized all the same even though it causes absolutely no psychoactive effects.

Aurora Cannabis Inc. is closing some of its European operations as the cannabis producer opts to consolidate its presence in the continent amid soft demand for medical pot, according to an internal memo obtained by BNN Bloomberg. 

Aurora told its employees last week that it will shut its offices in Portugal, Spain, and Italy while reducing its European workforces by one-quarter in select countries and its regional office, the memo said. The Edmonton-based company will shift its European headquarters from Germany to its Denmark office while acquiring the remaining 49 per cent of its Danish business that it doesn't already own, the company said. 

As any marijuana stock investor can tell you, the past 15 months haven't been pretty for pot stocks. Since April 2019, the vast majority of cannabis stocks have lost 50% or more of their value as growing pains have taken shape. In Canada, supply issues have led to everything from shortages to bottlenecks. Meanwhile, high tax rates on legal product in the U.S. have ensured that black market demand remains robust.